Listen On
In this episode of the CanadianSME Small Business Podcast, our host Maheen, sit down with Liran Belenzon, CEO of BenchSci, to explore how AI is transforming the biotech industry and what it takes to scale a high-impact startup in Canada’s competitive tech ecosystem.
With AI-driven drug discovery projected to grow at a CAGR of 40% by 2030, BenchSci has emerged as a global leader, partnering with 16 of the top 20 pharmaceutical companies and securing over $200 million in funding from investors like Google’s Gradient Ventures and Al Gore’s Generation Investment Management.
Key Highlights:
- The Future of AI in Biotech – How AI is accelerating drug discovery and transforming scientific research.
- Scaling a Biotech Startup – The biggest challenges BenchSci faced and how they overcame them.
- Securing Top-Tier Investors – Strategies for attracting funding from Google’s Gradient Ventures and other major backers.
- Building High-Performance Teams – How BenchSci scaled from a small startup to a 300+ person global biotech leader.
- What’s Next for BenchSci – The biggest biotech and AI breakthroughs to watch for in the next five years.
Special Thanks to Our Partners:
RBC: https://www.rbcroyalbank.com/dms/business/accounts/beyond-banking/index.html
UPS: https://solutions.ups.com/ca-beunstoppable.html?WT.mc_id=BUSMEWA
Constant Contact: https://www.constantcontact.com/landing1/new-marketer?utm_campaign=canadiansme&utm_medium=sponsorlogo&utm_source=brand
IHG Hotels and Resorts: https://businessedge.ihg.com/s/registration?language=en_US&CanSME
Google: https://www.google.ca/
For more expert insights, visit www.canadiansme.ca and subscribe to the CanadianSME Small Business Magazine. Stay innovative, stay informed, and thrive in the digital age!
Disclaimer: The information shared in this podcast is for general informational purposes only and should not be considered as direct financial or business advice. Always consult with a qualified professional for advice specific to your situation.
